Treatment
SHR-1826 clinical trials
We’re tracking 6 recruiting studies that include SHR-1826, each written for real people, not researchers, below.
Recruiting studies
- NCT06703177RecruitingPhase 1/Phase 2
Study of SHR-1826 combo for advanced solid tumors
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06915142RecruitingPhase 2
Study of HRS-7058 combined with cancer drugs for advanced solid tumors
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06754930RecruitingPhase 1/Phase 2
Study of SHR-1826 combined with other treatments for lung cancer
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06844474RecruitingPhase 2
Study of SHR-1826 for advanced lung cancer
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06094556RecruitingPhase 1
A study of SHR-1826 for advanced solid tumors
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07489716RecruitingPhase 2
Study of SHR-1826 for advanced non-small cell lung cancer
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Jinan, ShandongAges 18–75
What SHR-1826 is being studied for
Conditions with recruiting SHR-1826 studies.
Common questions
- Are there clinical trials studying SHR-1826?
- Yes. Clin2 currently lists 6 recruiting studies that include SHR-1826, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SHR-1826 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SHR-1826 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SHR-1826 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.